Insulin

Insulin is a peptide hormone secreted by the beta cells of the pancreas in response to rising blood glucose. Its primary function is to facilitate the uptake of glucose into cells, where it can be used for energy or stored as glycogen. But insulin is not merely a gatekeeper for sugar. It is a signaling molecule with reach into nearly every tissue in the body, including the brain. It modulates lipid metabolism, protein synthesis, inflammation, and vascular tone. It influences hunger and satiety through interaction with leptin and ghrelin. It crosses the blood-brain barrier and binds to receptors in the hippocampus, prefrontal cortex, and hypothalamus, where it affects cognition, mood regulation, and reward processing. When the system works well, insulin operates quietly in the background, maintaining metabolic equilibrium. When it does not—when cells become less responsive to insulin's signal and the pancreas compensates by producing more—the result is hyperinsulinemia, a state that precedes and often drives insulin resistance. Over time, this dysregulation contributes to a cascade of metabolic and neurological consequences that extend far beyond the regulation of blood sugar.

Insulin resistance is not a niche concern. It affects an estimated one in three adults in the United States, many of whom remain undiagnosed. It sits upstream of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, and certain cancers. But its influence does not stop at the neck. Emerging evidence links chronic hyperinsulinemia and insulin resistance to depression, anxiety, cognitive decline, and Alzheimer's disease, sometimes referred to as "type 3 diabetes" in the research literature. The brain is an insulin-sensitive organ. When insulin signaling becomes impaired, so too does synaptic plasticity, neurogenesis, and the clearance of amyloid-beta plaques. Mood becomes more volatile. Energy dips. Focus falters. These are not vague complaints. They are the lived experience of a nervous system operating in a metabolic environment it was not designed to sustain. What makes insulin resistance particularly insidious is its silence. There is no pain, no rash, no acute event. It develops gradually, often over years, beneath the surface of routine blood work that checks only fasting glucose—a measure that may remain normal even as insulin climbs. By the time glucose becomes elevated, the underlying dysfunction is often well established. This is why insulin resistance matters not only as a clinical diagnosis but as a framework for understanding how the body and brain communicate, and how that communication can quietly break down in ways that shape daily life long before disease is named.

It also matters because insulin resistance is largely reversible. Unlike many chronic conditions that require lifelong pharmaceutical management, insulin sensitivity can be restored through changes in diet, movement, sleep, and stress regulation. The Diabetes Prevention Program demonstrated that lifestyle intervention reduced the incidence of type 2 diabetes by fifty-eight percent over three years, more effectively than metformin alone (Knowler et al., 2002). That reversal is not merely statistical. It translates into improved energy, sharper cognition, more stable mood, and a quieter inflammatory background. The nervous system becomes more responsive, more resilient. Understanding insulin resistance offers a rare opportunity: the chance to intervene before irreversible damage occurs, and to do so with tools that are accessible, evidence-based, and within reach of most people willing to engage with them.

Insulin's role in glucose homeostasis has been understood since the early twentieth century, but its broader metabolic and neurological functions have come into sharper focus in recent decades. Reaven (1988) introduced the concept of Syndrome X, later termed metabolic syndrome, describing a cluster of conditions—hyperinsulinemia, hypertension, dyslipidemia, and central adiposity—that share insulin resistance as a common underlying feature. This framework reshaped how clinicians think about cardiovascular risk and metabolic disease. More recently, attention has turned to the brain. Insulin receptors are densely expressed in the hippocampus and prefrontal cortex, regions critical for memory and executive function. Craft and Watson (2004) demonstrated that intranasal insulin administration improved memory performance in adults with mild cognitive impairment, suggesting that restoring insulin signaling in the brain may have therapeutic potential. Conversely, peripheral insulin resistance appears to impair central insulin sensitivity. De la Monte and Wands (2008) proposed that Alzheimer's disease represents a form of brain-specific insulin resistance, characterized by deficits in insulin signaling, glucose metabolism, and mitochondrial function in neurons. Subsequent work has supported this model, linking elevated fasting insulin and poor glycemic control to accelerated cognitive decline and increased amyloid deposition. The relationship between insulin and mood is similarly robust. Pearson et al. (2010) found that insulin resistance, measured by HOMA-IR, was associated with increased depressive symptoms in a large population-based cohort, independent of body mass index. Anderson et al. (2001) reported that individuals with diabetes have roughly double the prevalence of depression compared to the general population, a finding that holds even after controlling for the psychosocial burden of chronic illness. Mechanisms likely include insulin's effects on serotonin and dopamine signaling, inflammatory cytokine production, and hypothalamic-pituitary-adrenal axis regulation. Insulin resistance is also a state of chronic low-grade inflammation. Elevated insulin promotes the release of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha, which in turn impair insulin receptor signaling, creating a self-reinforcing loop. Hotamisligil (2006) described this interplay as central to the pathogenesis of metabolic disease. Importantly, insulin resistance is modifiable. Knowler et al. (2002), in the Diabetes Prevention Program, showed that lifestyle intervention—focused on weight loss, physical activity, and dietary change—reduced the incidence of type 2 diabetes by fifty-eight percent, more effectively than metformin. Exercise, particularly resistance training and high-intensity interval training, improves insulin sensitivity through mechanisms that include increased GLUT4 translocation, enhanced mitochondrial biogenesis, and reduced visceral adiposity. Sleep also plays a critical role. Spiegel et al. (1999) demonstrated that even partial sleep deprivation over several nights significantly impairs glucose tolerance and insulin sensitivity, effects that are reversible with sleep recovery. Dietary composition matters as well. Diets low in refined carbohydrates and high in fiber, healthy fats, and protein have been shown to improve markers of insulin sensitivity and reduce postprandial glucose excursions.

Nervous System Intelligence begins with the recognition that the brain does not operate in metabolic isolation. It is an energy-intensive organ, consuming roughly twenty percent of the body's glucose despite representing only two percent of body weight. Its function depends not only on the availability of fuel but on the integrity of the signaling systems that regulate fuel delivery and utilization. Insulin is one of those systems. Within the NSI framework, insulin is understood as a messenger between the periphery and the central nervous system, a molecule that carries information about nutritional state, energy balance, and metabolic capacity. When that message is clear, the nervous system can allocate resources efficiently—supporting attention, emotional regulation, learning, and repair. When the message becomes garbled, as it does in insulin resistance, the nervous system must operate under constraint. This is not a failure of willpower or mood. It is a systems-level problem. NSI does not treat metabolic health as separate from neurological or psychological health. It treats them as expressions of the same underlying biology. Insulin resistance is therefore not merely a risk factor for future disease. It is a present-day disruptor of nervous system function. It affects the substrates required for neurotransmitter synthesis, the inflammatory tone of the brain, the plasticity of synapses, and the resilience of neurons under stress. Addressing insulin sensitivity is not ancillary to mental health care. It is foundational. This perspective shifts the clinical conversation. Rather than asking whether someone has diabetes, we ask whether their metabolic state supports the kind of nervous system function they are trying to build. Rather than waiting for pathology, we intervene at the level of pattern—sleep, movement, nutrition, circadian alignment—because those are the inputs that shape insulin signaling day to day.

Metabolic screening should be standard in any comprehensive evaluation of mental health, particularly in cases of treatment-resistant depression, cognitive complaints, fatigue, or atypical presentations of anxiety. Fasting glucose alone is insufficient. Fasting insulin, hemoglobin A1c, and calculated indices such as HOMA-IR provide a more complete picture of insulin dynamics. Lipid panels and liver enzymes can offer additional context. Many patients with normal fasting glucose have significantly elevated insulin, a pattern that reflects compensatory hyperinsulinemia and early-stage resistance. Clinicians should also consider the timing of symptoms. Does the patient experience mood or energy crashes in relation to meals. Is there a pattern of carbohydrate craving, brain fog after eating, or difficulty with sustained focus. These are not incidental details. They are clues to how the nervous system is responding to metabolic load. When insulin resistance is identified, the conversation should be framed not as a diagnosis of failure but as an opportunity for intervention. Lifestyle modification is first-line, and the evidence base is strong. This includes structured physical activity, prioritization of sleep, reduction of ultra-processed foods, and in some cases time-restricted eating or carbohydrate moderation. Metformin may be appropriate in certain contexts, particularly when lifestyle change alone is insufficient or when there is concurrent polycystic ovary syndrome. GLP-1 agonists are increasingly used and show promise not only for glycemic control but for weight reduction and possibly neuroprotection, though long-term data in psychiatric populations remain limited. Collaboration with endocrinology, nutrition, and health coaching can be invaluable. Importantly, clinicians must recognize that metabolic intervention is not a replacement for psychopharmacology or psychotherapy when indicated. It is an adjunct, and often a powerful one. Patients deserve to know that their metabolism is not separate from their mental experience. It is part of the terrain.

Your metabolism influences your mood. That is not a metaphor. It is measurable biology. If you experience unexplained fatigue, difficulty concentrating, mood swings tied to meals, or a sense that your body is working against you, it may be worth investigating your insulin sensitivity. Start with your primary care provider. Ask for fasting glucose, fasting insulin, and hemoglobin A1c. If those are unavailable, A1c alone is a reasonable starting point. Consider how you eat. Not in moral terms, but in mechanical ones. Do you go long stretches without food and then eat rapidly. Do you rely heavily on refined carbohydrates—bread, pasta, sweets, sugary drinks. These are not inherently bad, but they create sharp glycemic peaks and insulin surges that, over time, can desensitize the system. Prioritize protein and fiber at each meal. They slow gastric emptying and blunt the glucose response. Move your body regularly, and if possible, include resistance training. Muscle is the largest insulin-sensitive tissue in the body. When you contract a muscle, it takes up glucose independent of insulin, and over time, this improves baseline sensitivity. Walk after meals if you can. Even ten minutes makes a difference. Sleep is non-negotiable. Aim for consistency in timing as much as duration. Chronic sleep restriction is one of the fastest ways to induce insulin resistance, and it is also one of the most reversible. If you are working with a therapist or psychiatrist, bring your metabolic health into the conversation. It is not tangential. It is part of the picture. And if you are told that your labs are normal, ask what was measured. Normal fasting glucose does not mean your insulin is normal. You are not broken. But you may be operating in a metabolic context that makes everything harder than it needs to be.